• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
?
-

Resources for You

Novoeight

STN: BL 125466
Proper Name: Antihemophilic Factor (Recombinant)
Tradename: Novoeight
Manufacturer: Novo Nordisk 

Indication: 

  • For adults, adolescents, and children with hemophilia A for (1) the control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Note:  The FDA approval of Novoeight is an activity that is funded under FDA’s user fee program in the Center for Biologics Evaluation and Research. Some FDA activities that do not rely on annual appropriations are continuing during the government shutdown.